Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
11.68
+0.38 (3.36%)
Dec 20, 2024, 4:00 PM EST - Market closed
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 21.83, with a low estimate of 13 and a high estimate of 35. The average target predicts an increase of 86.90% from the current stock price of 11.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for STOK stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +105.48% | Dec 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +199.66% | Nov 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +88.36% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +199.66% | Sep 11, 2024 |
Financial Forecast
Revenue This Year
17.88M
from 8.78M
Increased by 103.66%
Revenue Next Year
15.48M
from 17.88M
Decreased by -13.43%
EPS This Year
-2.08
from -2.38
EPS Next Year
-2.52
from -2.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 19.8M | 47.3M | 72.5M | |||
| Avg | 17.9M | 15.5M | 23.0M | |||
| Low | 13.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 126.0% | 164.2% | 368.3% | |||
| Avg | 103.7% | -13.4% | 48.7% | |||
| Low | 55.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.10 | -2.36 | -2.19 | |||
| Avg | -2.08 | -2.52 | -2.53 | |||
| Low | -2.07 | -2.76 | -2.98 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.